BERLIN--(EON: Enhanced Online News)--EBS Technologies (“EBS”) announced today that Charité Berlin, one of the largest university hospitals in Europe, has successfully treated its first patient with the EBS NEXT WAVE™ brain stimulation device designed to expand the visual field of patients with impaired vision, e.g. caused by optic nerve damage.
“the start of an improvement process. Given that there was nothing else available to me, I am very thankful and very optimistic.”
“I now have hope,” said Hans-Joerg Hehli, 58, who lost his central vision due to anterior ischemic optic neuropathy (AION), a medical condition involving a relative loss of vision due to damage to the optic nerve, the result of insufficient blood supply. Mr. Hehli has been unable to work as project manager for a machine tool company because of his near-total central vision loss in both eyes. Then, less than two weeks after receiving 10 consecutive days of 40-minute treatments with NEXT WAVE™ therapy at Charité Berlin, Mr. Hehli says his central vision field has improved significantly; using the sophisticated methodology of a computerized visual field analyzer (Octopus ® 900). Doctors at Charité Berlin confirmed that 33 absolute visual defects have been reduced to two in Mr. Hehli’s left eye and 48 “relative visual defects” reduced to 17 in his right eye after NEXT WAVE™ therapy. Mr. Hehli believes he is now at “the start of an improvement process. Given that there was nothing else available to me, I am very thankful and very optimistic.”
“No doubt, there is a very significant unmet clinical need for the treatment of vision impairment caused by a variety of different neurological disorders, such as neuropathy of the optic nerve, as is the case with Mr. Hehli. Three out of five persons who are disabled from impaired vision as a result of optic nerve neuropathy, brain injury, or stroke are potentially treatable with our NEXT WAVE™ therapy, which is why we are very excited about Charité’s pioneering role in validating NEXT WAVE™ therapy,” said Ulf Pommerening, CEO of EBS Technologies. “Nevertheless we recognize that further research is necessary to validate this in patients with various disease etiologies.”
In June 2013, EBS announced the results of a multi-center, 82-patient clinical trial of its NEXT WAVE™ brain stimulation device. About one-half of the clinical trial patients were given a 40-minute treatment protocol for 10 consecutive days with the NEXT WAVE™ device. With an average increase of 24% of the total visual field, NEXT WAVE™-treated patients showed significantly better improvements in stimulation of their total visual field compared to patients in the control group, which did not receive NEXT WAVE™ stimulation. All patients had vision impairment lasting at least six months prior to the clinical trial and had exhausted all standard therapeutic options to improve their vision.
About NEXT WAVE™
The NEXT WAVE™ technology enables a unique revitalization of selective communication paths between neurological cells, which may have been impaired due to brain injury caused by e.g. trauma, degeneration or tumor resection. The non-invasive therapy utilizing the patented NEXT WAVE™ technology is clinically validated to restore vision impairment by 20 to 30 percent after brain dysfunction. In addition, glaucoma patients have shown to benefit from the NEXT WAVE™ technology.
NOTE: NEXT WAVE™ is approved for sale in Europe; it is not approved for sale or investigational use in the U.S.